

Adult CIRB - Late Phase Emphasis Meeting Agenda

September 18, 2025

I Continuing Review

A031702, A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) (Version Date 08/01/25)

II Continuing Review

A041202, A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL) (Version Date 05/21/25)

III Continuing Review

A081801, Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) (Version Date 06/11/25)

IV Continuing Review

A082101, Multimodality Therapy with Immunotherapy in Stage I-III A Pleural Mesothelioma (Version Date 08/01/25)

V Continuing Review

A091903, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma (Version Date 08/12/25)

VI Continuing Review

A092107, A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma (Version Date 04/04/25)

VII Continuing Review

CCTG-PR26, A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) (Version Date 06/20/25)

VIII Continuing Review

EA8134, InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) (Version Date 02/16/23)

IX Continuing Review

NRG-LU008, Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (Version Date 08/05/25)
